Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782834 · ClinicalTrials.gov registry record · Phase 2
Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00782834 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 13 participants.
The verdict
NCT00782834, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a phase II study of Nilotinib for patients with advanced GIST that cannot be surgically removed. Patients are candidates for the study if their tumors have progressed on imatinib and sunitinib or if they were intolerant to these drugs. Patients may have received other investigational therapies as well. We are testing the benefit of nilotinib in advanced GIST looking at the length of time disease is controlled as well as the response of the disease to the drug.
Interventions
- DRUG Nilotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782834
The ClinicalTrials.gov registry entry for NCT00782834 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nilotinib is the first listed.
NCT00782834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782834 about?
NCT00782834 is a clinical study titled "Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)". This is a phase II study of Nilotinib for patients with advanced GIST that cannot be surgically removed. Patients are candidates for the study if their tumors have progressed on imatinib and sunitinib or if they were intolerant to these drugs. Patients may have received other investigational therapi...
What is the current status of trial NCT00782834?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2008-07. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00782834?
The interventions under investigation include: Nilotinib (DRUG).
Who is sponsoring clinical trial NCT00782834?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.